BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, Mammasse N, Ona V, Bachmann A, Strugala D, Reh C, Goteti K. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol Res Perspect 2021;9:e00842. [PMID: 34414672 DOI: 10.1002/prp2.842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alexopoulou L. Nucleic acid-sensing toll-like receptors: Important players in Sjögren’s syndrome. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.980400] [Reference Citation Analysis]
2 Yamakawa N, Tago F, Nakai K, Kitahara Y, Ikari S, Hojo S, Hall N, Aluri J, Hussein Z, Gevorkyan H, Maruyama T, Ishizaka S, Yagi T. First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers. Clin Pharmacol Drug Dev 2022. [PMID: 36219471 DOI: 10.1002/cpdd.1176] [Reference Citation Analysis]
3 Dai J, Wang Y, Wang H, Gao Z, Wang Y, Fang M, Shi S, Zhang P, Wang H, Su Y, Yang M. Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019. Front Microbiol 2022;13:948770. [DOI: 10.3389/fmicb.2022.948770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Aringer M, Alarcón-riquelme ME, Clowse M, Pons-estel GJ, Vital EM, Dall’era M. A glimpse into the future of systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210867. [DOI: 10.1177/1759720x221086719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]